Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo
ESR-21-21284
Phase 2 small_molecule active
Quick answer
Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo for Sjogren's disease is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Sjogren's disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active